Eisai wins over European regulators on Alzheimer’s drug Leqembi

In an unusual reversal, key drug regulators in Europe are now saying Leqembi, a high-profile medicine for Alzheimer’s disease, should be approved there, though only for patients less likely to experience a certain kind of concerning side effect.